Self Monitoring of Blood Glucose (SMBG) in Non-Insulin treated
Type 2 Diabetes

NZSSD Executive Position Statement

Results from two recent randomised controlled trials suggest that self-monitoring of blood glucose in patients with non-insulin treated Type 2 diabetes does not improve glycaemic control and may impair quality of life. [1, 2] However there are some people with non-insulin treated Type 2 diabetes who are highly likely to benefit from using SMBG and the Executive considers that clinical judgement should be used to determine who these individuals are. This group would include those with dysglycaemia (hyper or hypoglycaemia), intercurrent illness and treatment with sulphonylureas in whom SMBG may provide useful information for adjustment of therapy.

Accepted January 2009
Amended and accepted 20 February 2009

NZSSD Executive

References

  1. Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008; 336: 1177-80.
  2. O’Kane MJ, Bunting B, Copeland M, et al. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008; 336: 1174-7.